Baraclude - After Plavix, Baraclude is the next significant challenge that BMS will have to face immediately.
FORBES: Looking At Bristol-Myers Squibb's Major Patent Expiries That Will Drag On Growth
But as Jeremy Levin of BMS often says, partnering and investing are different and require different mindsets.
The opportunity to work with BMS made sense for them both from a competitive and financial sense.
The third is Vicki Sato, who serves on the BMS Board, and was formerly of Vertex and Biogen.
FORBES: Change Starts at the Top: Imperative to Bring Biotech Voices to Pharma Boardrooms
This compound, a factor Xa inhibitor, was discovered and advanced into the clinic by Bristol-Myers Squibb (BMS).
If true, both BMS and Pfizer will have made a great decision to combine resources in this program.
The trouble with BMS-094 points the way toward the second, and far more difficult, change the industry needs to make.
Second, Bristol-Myers Squibb stopped a Phase II study of its BMS-094 for hepatitis C because of a serious safety issue.
When BMS was getting ready to start late stage clinical trials, they decided to seek a development and co-marketing partner.
Pfizer had their own factor Xa inhibitor in development , but it was at least a year behind the BMS program.
The CODA Battery Management System (BMS) works with ATMS to regulate charging.
FORBES: 2012 CODA Sedan -- Changing Perceptions Of All-Electric
Bemis (BMS) reports its fourth quarter earnings on Thursday, January 31, 2013.
Bristol is testing it in combination with two other experimental drugs code-named BMS-790052 and BMS-650032 that are in mid-stage trials, and also two earlier-stage compounds.
The introduction of bare metal stents (BMS) produced a significant improvement.
Amira was in a similar ballpark before BMS picked them up.
FORBES: Gravity, Biotech Returns, and Why The Median Matters
The suit alleges that, despite the negative data, on at least nine occasions during the clinical trial period--January 1998 through November 1999--BMS execs and its paid consultants heaped praises on the drug.
According to the ETF Finder at ETF Channel, BMS makes up 1.42% of the Dynamic Basic Materials Sector Portfolio ETF ( AMEX: PYZ )which is trading lower by about 0.2% on the day Wednesday.
应用推荐